Standard Biotools (LAB) Cash & Equivalents (2010 - 2026)

Standard Biotools (LAB) has 17 years of Cash & Equivalents data on file, last reported at $265.8 million in Q1 2026.

• Quarterly Cash & Equivalents rose 73.17% year-over-year to $265.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $265.8 million (up 73.17% YoY) and the FY2025 annual result came in at $120.9 million, down 28.41% from the prior year.
• Cash & Equivalents grew to $265.8 million in Q1 2026 per LAB's latest filing, from $120.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $288.3 million in Q1 2024 and bottomed at $31.0 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $129.4 million (2025), against an average of $141.7 million.
• The widest annual swing landed in 2023, when Cash & Equivalents jumped 269.23%; it then tumbled 46.78% in 2025.
• Tracing LAB's Cash & Equivalents over 5 years: stood at $82.3 million in 2022, then tumbled by 36.23% to $52.5 million in 2023, then soared by 221.56% to $168.8 million in 2024, then declined by 28.41% to $120.9 million in 2025, then surged by 119.9% to $265.8 million in 2026.
• Per Business Quant, the three latest LAB Cash & Equivalents figures stand at $265.8 million (Q1 2026), $120.9 million (Q4 2025), and $129.4 million (Q3 2025).

Peer Comparison